Dong-A ST
동아에스티 · 170900
Health Care Pharmaceuticals · KOSPI
Market cap US$272.1M (₩375.5B)
Overview
Dong-A ST makes prescription medicines, drugs that require a doctor's order, along with medical devices and related health-care products, supplying hospitals, clinics, and pharmacies in Korea.
It is listed on KOSPI, Korea's main stock exchange. The company's portfolio includes several drugs it developed in-house, such as treatments for erectile dysfunction, gastrointestinal motility, and diabetes, and it manufactures products at three domestic facilities. Its active research pipeline focuses on new drugs for metabolic diseases including diabetes, obesity, and a liver condition known as MASH.
Summary is AI-generated and may contain errors · figures from DART filings
Financials
Source: DART · FY ending Dec · latest FY2025Revenue
- FY2023US$481.1M
- FY2024US$505.7M
- FY2025US$586.1M
Operating profit
- FY2023US$8.1M
- FY2024−US$18.1M
- FY2025US$451.6K
Net income
- FY2023US$1.5M
- FY2024−US$16.8M
- FY2025−US$27.3M
Key ratios (FY2025)
Why it matters
Dong-A ST was spun off from 동아쏘시오홀딩스 (formerly Dong-A Pharmaceutical) as an independent prescription-drug business.
Price charts coming soon
Interactive price history isn't here yet. Would you use it?